<DOC>
	<DOCNO>NCT03080116</DOCNO>
	<brief_summary>RATIONALE : Neoadjuvant hormonal therapy use luteinizing hormone release hormone ( LHRH ) agonists and/or anti-androgens already demonstrate downstage primary prostate cancer patient treat radical prostatectomy without survival benefit . There evidence yet survival impact LHRH antagonist ( LHRHa ) +/- new-generation anti-androgens set . Thus novel study need assess treatment combination . PURPOSE : To assess difference treatment antitumor effect arm measure pathological tumor volume minimal residual disease ( MRD ) follow radical prostatectomy + pelvic lymph-node dissection ( RP + PLND ) intermediate high-risk prostate cancer patient .</brief_summary>
	<brief_title>Neoadjuvant Degarelix +/- Apalutamide ( ARN-509 ) Followed Radical Prostatectomy</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : To assess difference antitumor effect treatment arm measure MRD follow radical prostatectomy . SECONDARY OBJECTIVES : To measure difference study arm - Proportions post neoadjuvant prostate specific antigen ( PSA ) ≤ 0.3 ng/ml predictor prostate cancer mortality - T down-staging , complete pathological response , PSA kinetics , Testosterone kinetics , operation time , blood loss , grade surgical difficulty - New generation hybrid image 68Ga PSMA ( Prostate-Specific Membrane Antigen ) PET/MR ( Positron emission tomography/Magnetic Resonance ) derive parameter - Early biochemical recurrence prognostic factor prostate cancer mortality - Transcriptome genome - Tissue microarrays ( TMA ) protein expression ( DNA repair , resistance etc . ) immunohistochemistry - Perioperative safety tolerability - Quality life , erection recovery , continence validate preoperative postoperative questionnaire pre postop ( IEEF5 , ICIQ , EORTC QLQ-C30 ) OUTLINE : interventional , single center , phase II , randomize , double blind , placebo control trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial 2 . Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation 3 . Male age 18 year old ( within 80 year ) 4 . Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature 5 . Diagnosis intermediate ( least 2 follow factor : cT2b , biopsy GS 7 , PSA 1020ng/ml ) highrisk prostatic adenocarcinoma ( clinical stage≥T2c and/or biopsy GS≥8 and/or PSA &gt; 20ng/ml ) , cN0cN1 , cM0 . 6 . Patient amenable open robotic radical prostatectomy + pelvic lymph node dissection 7 . ECOG performance status : 01 8 . Adequate organ function define follow criterion : White blood cell ( WBC ) ≥ 4.0 x109/L Platelet count ≥ 100 x109/L Hemoglobin ≥9 g/dl Creatinine ≤ 2 x ULN Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) ≤ 2.5 x upper limit normality ( ULN ) Total serum bilirubin ≤1.5 x ULN . 1 . Previous surgical/endoscopic treatment prostatic disease 2 . Herbal nonherbal product opinion investigator may decrease PSA level 3. cM1 disease 4 . Any contraindication PET MR investigation 5 . History seizure condition may predispose seizure ( e.g. , prior stroke within 1 year prior randomization , brain arteriovenous malformation , Schwannoma , meningioma , benign CNS meningeal disease may require treatment surgery radiation therapy ) 6 . Medications know low seizure threshold 7 . History : Any prior malignancy ( adequately treat basal cell squamous cell skin cancer , superficial bladder cancer currently complete remission ) within 5 year prior randomization Severe/unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( e.g. , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior randomization Uncontrolled hypertension ( systolic blood pressure ≥160 mmHg diastolic BP ≥100 mmHg ) . Patients history uncontrolled hypertension allow provide blood pressure control antihypertensive treatment . Gastrointestinal disorder affect absorption 8 . Any condition , opinion Investigator , would impair patient 's ability comply study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Androgen deprivation</keyword>
	<keyword>Antiandrogen</keyword>
	<keyword>Radical Prostatectomy</keyword>
</DOC>